Breaking News
Subscribe Now 0
👀 Ones to watch: Undervalued stocks to buy before they report Q3 earnings See Undervalued Stocks
Close

Gilead Sciences Inc (GILD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
78.7900 -0.1700    -0.22%
- Delayed Data. Currency in EUR
Type:  Equity
Market:  Germany
ISIN:  US3755581036 
WKN:  885823
  • Volume: 32
  • Bid/Ask: 78.7400 / 78.9500
  • Day's Range: 78.2800 - 78.7900
Gilead 78.7900 -0.1700 -0.22%

NASDAQ:GILD Financials

 
A brief overview of the NASDAQ:GILD financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Gilead over time.

Gilead Sciences, Inc. reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported revenue was USD 6,954 million compared to USD 6,599 million a year ago. Net income was USD 1,614 million compared to USD 1,045 million a year ago. Basic earnings per share from continuing operations was USD 1.29 compared to USD 0.84 a year ago. Diluted earnings per share from continuing operations was USD 1.29 compared to USD 0.83 a year ago.For the six months, revenue was USD 13,640 million compared to USD 12,951 million a year ago. Net loss was USD 2,556 million compared to net income of USD 2,055 million a year ago. Basic loss per share from continuing operations was USD 2.05 compared to basic earnings per share from continuing operations of USD 1.65 a year ago. Diluted loss per share from continuing operations was USD 2.05 compared to diluted earnings per share from continuing operations of USD 1.63 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

GILD Income Statement

Gross margin TTM 77.44%
Operating margin TTM 38.5%
Net Profit margin TTM 3.79%
Return on Investment TTM 19%
 Total Revenue  Net Income
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Revenue 6953 6686 7114 7050
Gross Profit 5409 5134 5503 5485
Operating Income 2692 2302 3003 2715
Net Income 1614 -4170 1429 2180

GILD Balance Sheet

Quick Ratio MRQ 0.78
Current Ratio MRQ 1.14
LT Debt to Equity MRQ 117.83%
Total Debt to Equity MRQ 127.73%
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Assets 53579 56292 62125 62373
Total Liabilities 35382 38837 39376 40131
Total Equity 18197 17455 22749 22242

GILD Cash Flow Statement

Cash Flow/Share TTM 5.99
Revenue/Share TTM 22.32
Operating Cash Flow  12.29%
 Cash  Net Change in Cash
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 1325 2219 2169 1755
Cash From Investing Activities -307 -2207 -727 -229
Cash From Financing Activities -2953 -1361 -1099 -1519
Net Change in Cash -1946 -1367 380 1
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GILD Comments

Write your thoughts about Gilead Sciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Giuseppe Giannachi
Giuseppe Giannachi Jun 20, 2024 11:38AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The news seems amazing. 100% AIDS prevention...?
Maria Kenny
Maria Kenny Jun 11, 2024 9:31AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Acquisition decreased EPS. This has 40% upside by January 2025. Hold. Do not sell.
Luis Anderson
Luis Anderson Jul 14, 2023 9:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
time to buy
Bugman CV
Bugman CV Apr 28, 2022 1:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Who cares about dividends when this stock shows weakness year after year, is not a good deal to get 5% per year if you are constantly worried about this stock sinks under 2013 lows
Jorge Almeida Pereira
Jorge Almeida Pereira Apr 28, 2022 1:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Are you a coinbase client?
Luis Anderson
Luis Anderson Apr 28, 2022 1:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Keith Chan
Keith Chan Mar 08, 2022 10:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it sucks...
Dale Le
Dale Le Feb 17, 2022 9:37PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
invest stock gild.us at basel markets to take home divedends
Manny Drake
Manny Drake Jan 28, 2022 3:06PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Projected earnings beat but I'd bet it doesn't move the needle -
Tedeski Rukker
Tedeski Rukker Jan 07, 2022 6:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Another 15 or so shares into this.
Ted Trukker
Ted Trukker Nov 19, 2021 2:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I've held this since 2014 or so. COULD have picked NVDA for approx 15 - 20 😒Did I pick the winner eh?
BIG John
BIG John Oct 29, 2021 9:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Amazing how GILD managed to disappoint on EVERY earnings report.
Ted Trukker
Ted Trukker Oct 29, 2021 9:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Yes, even a beat is disapointing -
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email